ncluding the Issue Fee Receipt, the Patent,	advance orders a	nd notification of maintenanc	ks 2 throug	the factor of th	unless you direct otherwis	
of Issue Fee or thereafter. See reverse for Under the Paperwork Reduction Act of 1995	Certificate of Ma 5, no persons are r	iling, below. equired to respond to a colle	ection of inf	ormation unless it displays a valid OMB con	21	
Burden Hour Statement: This form is estimated by the state of the individual case.		2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)				
complete this form should be sent to the Chi Washington, D.C. 20231.		INVENTOR'S NAME				
DO NOT SEND FEES OR COMPLETED FO Assistant Commissioner for Patents, Washir		Street Address	P. P.Con.			
1. CORRESPONDENCE ADDRESS		City, State and ZIP Code	MA SED			
TACCORDE C HONOR	A /	12M1/1/216	0,	CO-INVENTOR'S NAME	WA I 7 TON	
ROBERT S HONOR SANDOZ CORPORA	TICAPEN		Street Address	2 1997		
· 59 ROUTE 10	1.47	n la	$\emptyset EC[j]$	City, State and ZIP Code	Uq /	
EAST HANOVER N	J 07936-1	ENTERE	Yon	Check if additional changes are enclose	d	
* APPLICATION NO.	FILING DATE	TOTAL CLAIMS		EXAMINER AND GROUP ART UNIT	DATE MAILED	

BOND, R

1202

12/16/96

TITLE OF INVENTION O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

SYLVAIN

009

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. T	YPE	SMALL ENTITY	FEE DUE	E DUE DATE DUE												
1 100-7932/PCT 514-514.000 H50 UTI					LITY NO \$1290.00 03/17/97														
Correspondence address change (Complete only if there is a change)				list the	n the patent front names of not more than latent attorneys or agent	'	t S.	Honor											
			OR, a	ltemativ g as a m	atively, the name of a firm a member a registered agent. If no name is listed,	2 Melvy	n M.	Kassenoff											
				no name will be printed.		•	s 0.	McGovern											
5. ASSIGNMENT DATA TO BE PRINTED ON	THE PATENT (print or type)																		
(1) NAME OF ASSIGNEE: SANDOZ LTD.  (2) ADDRESS: (CITY & STATE OR COUNTRY) Basle, Switzerland  A.  This application is NOT assigned.					6a. The following fees are enclosed:  ☐ Issue Fee ☐ Advance Order - # of Copies  6b. The following fees should be charged to:  DEPOSIT ACCOUNT NUMBER														
Assignment previously submitted to the Patent and Trademark Office.  Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.  PLEASE NOTE: Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.					Many Deficiencies in Enclosed Fees  The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application Identified above.  (Authorized-Signature)  (Date)  3 / 1 4 / 9 7  NOTE: The Issue Fee will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in Interest as shown by the records of the Patent and Trademark Office.														
											Note: If this certificate of mailing is us	ed it can only be used to tr		cate of Mall		a cannot ha usad for a	ny other accompan	vána nana	are
											Each additional paper, such as an as	signment or formal drawing,	must have its ov	wn certificate	of mail	ing.		ymy pape	
											I hereby certify that this corresponder an envelope addressed to: Box	nce is being deposited with t	he United States	Postal Serv	ce with				
Assi	stant Commissioner for Pa hington, D.C. 20231	atents	AO	1	190134	B1797	142	1290,00											
on: MARCH 14, 199		(Date)	Aa	1	190134	031797	561	30,00											
THOMAS O. MCGO			erson makin	depos	sit)														
	Hortha	(Signature)		· · · · · · · · · · · · · · · · · · ·															
MARCH 14, 199	<i>I</i>	(Date)		,															



First Named

Applicant

COTTENS,

Case No. 100-7932/PCT

#8/C 5/3/97 C Styles

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Sylvain Cottens, et al.

: Art Unit: 1202

Serial No. 08/416,673

Examiner: R. Bond

Filed: April 7, 1995

: Batch No.: H50

For: O-ALKYLATED RAPAMYCIN

DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Cummissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas O. McGovern

Name of applicant, assignee, or
Registered Representative

Signature
March 14, 1997
Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

### IN THE CLAIMS

Please cancel claim 4, 9, and 10.

In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term " $R_1$ ", and insert in its place in each instance the term --  $R^1$  --.

SL10147 04/17/97 08416673

3210147 04/17/97 08416673

19-0134 100 142


19-0134 100 561

1,290.00CH 30.00CU Claim 16, line 2; claim 17, line 4; and claim 18, line 3, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

Please add the following new claims 19 and 20.

19. A compound of the formula

10430×



wherein  $R^1$  is hydroxy( $C_{1-6}$ )alkyl or hydroxy( $C_{1-3}$ )alkoxy( $C_{1-3}$ )alkyl.

20. The compound according to claim 19 which is 40-0-(3-hydroxyethyl)-rapamycin.

#### REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R<sup>1</sup> has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R<sup>1</sup> has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred  $C_{1-3}$  alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.



The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

By <u>Nomis C M Bora</u> Thomas O. McGovern

Registration No. 25,741

(201) 503-8480

TOM: 1mc

NOVARTIS CORPORATION 59 Route 10 E. Hanover, N.J. 07936

March , 1997

Enclosures: COM Stamp; Postcard



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

